Effects of EPO on blood parameters and running performance in Kenyan athletes by Haile, Diresibachew W et al.
Effects of EPOAQ1 on Blood Parameters and
Running Performance in Kenyan Athletes
AQ2 DIRESIBACHEW W. HAILE1,2,3, JE´ROˆME DURUSSEL2, WONDYEFRAW MEKONEN1, NEFORD ONGARO3,
EDWIN ANJILA3, MARTIN MOOSES4, EVANGELIA DASKALAKI5, KERLI MOOSES4, JOHN D. MCCLURE2,
SHAUN SUTEHALL6, and YANNIS P. PITSILADIS7,8
1Department of Physiology, College of Health Sciences, Addis Ababa University, Addis Ababa, ETHIOPIA; 2Institute of
Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow,
UNITED KINGDOM; 3Department of Medical Physiology, School of Medicine, College of Health Sciences, Moi University,
Eldoret, KENYA; 4Faculty of Medicine, University of Tartu, Tartu, ESTONIA; 5Strathclyde Institute of Pharmacy and
Biomedical Sciences, University of Strathclyde, Glasgow, UNITED KINGDOM; 6Division of Exercise Science and Sports
Medicine, Department of Human Biology, University of Cape Town, SOUTH AFRICA; 7Collaborating Centre of Sports
Medicine, University of Brighton, Brighton, UNITED KINGDOM; and Department of Movement, Human and Health Sciences,
University of Rome ‘‘Foro Italico,’’ Rome, ITALY
ABSTRACT
HAILE, D. W., J. DURUSSEL, W. MEKONEN, N. ONGARO, E. ANJILA, M. MOOSES, E. DASKALAKI, K. MOOSES, J. D.
MCCLURE, S. SUTEHALL, and Y. P. PITSILADIS. Effects of EPOAQ1 on Blood Parameters and Running Performance in Kenyan
Athletes. Med. Sci. Sports Exerc., Vol. 51, No. 2, pp. 00–00, 2019. Introduction: Recombinant human erythropoietin (rHuEpo) ad-
ministration enhances oxygen carrying capacity and performance at sea level. It remains unknown whether similar effects would be
observed in chronic altitude-adapted endurance runners. The aim of this study was to assess the effects of rHuEpo on hematological and
performance parameters in chronic altitude-adapted endurance runners as compared to sea level athletes.Methods: Twenty well-trained
Kenyan endurance runners (KEN) living and training at approximately 2150 m received rHuEpo injections of 50 IUIkgj1 body mass
every 2 d for 4 wk and responses compared with another cohort (SCO) that underwent an identical protocol at sea level. Blood samples
were obtained at baseline, during rHuEpo administration and 4 wk after the final injection. A maximal oxygen uptake (V˙O2max) test and
3000-m time trial was performed before, immediately after and 4 wk after the final rHuEpo injection. Results: Hematocrit (HCT) and
hemoglobin concentration (HGB) were higher in KEN compared to SCO before rHuEpo but similar at the end of administration. Before
rHuEpo administration, KEN had higher V˙O2max and faster time trial performance compared to SCO. After rHuEpo administration, there
was a similar increase in V˙O2max and time trial performance in both cohorts; most effects of rHuEpo were maintained 4 wk after the final rHuEpo
injection in both cohorts.Conclusions: Four weeks of rHuEpo increased the HGB and HCT of Kenyan endurance runners to a lesser extent than
in SCO (~17% vs ~10%, respectively) and these alterations were associated with similar improvements in running performance immediately
after the rHuEpo administration (~5%) and 4 wk after rHuEpo (~3%). Key Words: ENDURANCE PERFORMANCE, DOPING, CHRONIC
ALTITUDE EXPOSURE, EAST AFRICAN
R
ecombinant human erythropoietin (rHuEpo) admin-
istration has been shown to increase blood oxygen
carrying capacity and endurance performance in
normoxic conditions. For example, it has been shown that 4
to 6 wk of rHuEpo administration increased maximal oxygen
uptake (V˙O2max) by 6% to 8% (1–8), submaximal cycling
capacity at 80% of V˙O2max by ~54% using time to exhaustion
(9) and submaximal running performance by approximately
6% using 3000-m time trial (4). Hence, rHuEpo is, allegedly,
frequently subjected to abuse by athletes. Despite this over-
whelming evidence, some authors continue to question the
ergogenic potential of rHuEpo administration in elite athletes
and contend that the performance-enhancing effect of rHuEpo
is likely to be small or even nonexistent (10,11). In the most
recent of these studies, Heuberger et al. (10) reported that
rHuEpo administration enhanced V˙O2max by 10% in well-
trained cyclists but did not improve performance during
submaximal exercise test or road race performance. These au-
thors argue that time trial performance involving elite athletes
is determined by muscle oxidative capacity and to a lesser
extent oxygen delivery; hence the suggestion that rHuEpo en-
hances V˙O2max but not submaximal road racing performance.
This explanation is in stark contrast to a study that reported
greater gains in performance during submaximal than maximal
exercise after rHuEpo administration (9).
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In response to the extraordinary success of the Kenyan
and Ethiopian middle- and long-distance runners since the
1968 Mexico City Olympics, several factors have been
investigated (see (12) for review) in an attempt to explain
this East African running supremacy such as the fact that
most of these runners live and train at an altitude of ap-
proximately 2400 to 2700 m. For instance, the homeland
of the Kalenjin tribe, which is known to produce the vast
majority of the best runners in Kenya, is situated at 1830
to 2450 m (13). Specifically, it has been reported that
Kenyan runners have a very high V˙O2max, high running
efficiency, lower blood lactate accumulation, extremely
low ammonia accumulation during exercise and higher
3-hydroxyacyl-CoA-dehydrogenase than their European
counterparts (14,15).
Although chronic hypobaric and acute normobaric hyp-
oxia can lead to very different physiological responses, it
can be speculated that athletes residing at moderate altitude
may benefit even more from rHuEpo administration than
sea-level athletes due to the enhanced effects of rHuEpo on
V˙O2max at this altitude range (16). Robach et al. (16) com-
pared the ergogenic effects of rHuEpo during normobaric
hypoxia and normoxia in physically active subjects and
found that the relative improvement in V˙O2max induced by
rHuEpo administration was greater at a simulated altitude up
to 3500 m compared to normoxia, while above 3500 m,
V˙O2max remained unaltered by rHuEpo administration. Ad-
ministration of rHuEpo increased the arterial oxygen content
regardless of the severity of hypoxia; however, peak oxygen
delivery directed to the exercising legs was only enhanced
during normoxia. It remains unknown why the relative im-
provement in V˙O2max was more than doubled (i.e., 17.5 vs
~8%) at a moderate altitude up to 3500 m compared to
normoxia (16). Nonhematological mechanisms, such as
augmented buffer capacity, mood improvement, and placebo
effect, have all been proposed to account for the observed
changes in exercise performance in response to rHuEpo
administration (17,18).
In East Africa, where champions are continuously emerg-
ing and where being a successful runner is associated with
substantial socioeconomic rewards, athletes are subjected to
an environment with extreme pressure to perform (13). This
unique social, psychological, and economic situation may
increase the likelihood of doping behavior. Therefore, the
aim of this study was to assess the effects of rHuEpo ad-
ministration on hematological and performance parameters
in well-trained altitude-adapted endurance runners. More
specifically, whether rHuEpo at moderate altitude enhances
oxygen carrying capacity and indicators of performance in
chronic altitude adapted endurance runners. These unique
results will be compared with similar observations made in
a white cohort living and training at or near sea level that
underwent an identical rHuEpo administration regimen (4).
Furthermore, in the antidoping field, the Athlete Biological
Passport (ABP) uses intra-individual abnormal variability
over time in selected hematological parameters to indirectly
detect erythropoiesis-stimulating agents, such as rHuEpo (19).
In this context, knowledge of the hematological response af-
ter rHuEpo administration in athletes living and training at
moderate altitude is urgently required.
METHODS
Subjects. Twenty Kenyan endurance runners from the
Kalenjin tribe based at altitude (Eldoret, Kenya, ~2150 m
above sea level, PIO2: 115 mm Hg; age, 26.4 T 4.1 yr; body
mass, 56.6 T 4.7 kg; height, 171.8 T 6.4 cm) were recruited
for this study. Eighteen subjects were long distance runners
(personal best times, 5000 m: 14:22 T 0:47 min:s; 10,000 m:
29:43 T 1:2 min:s; half marathon, 1:03 T 0:14 h:min; mara-
thon, 2:12 T 0:19 h:min) and 2 were specialized in shorter
distances (800m: 01:50 T 0:3min:s; 1,500m: 3:49 T 0:4min:s).
On average, the group had been training for 5 T 2 yr and were
training in the same group with an average running distance of
128 T 25 kmIwkj1. This cohort (KEN) was compared with
a previously published cohort (SCO) of 19 white endur-
ance trained males based at or near sea level (Glasgow,
Scotland, PIO2, 150 mm Hg; age, 26.0 T 4.5 yr, body mass,
74.8 T 7.9 kg; height, 179.8 T 5.4 cm) that underwent an
identical rHuEpo administration regimen, a full description
of this study is available elsewhere (4).
All subjects underwent a medical assessment and pro-
vided written informed consent to participate. Subjects were
requested to maintain their normal training but abstain from
official sporting competition for the duration of the research
study. This study was approved by the Ethics Committees
of Moi University (Kenya) and University of Glasgow
(Scotland) and conformed to the Declaration of Helsinki.
Experimental design. Each subject subcutaneously
self-injected, under supervision, 50 IUIkgj1 body mass of
rHuEpo (NeoRecormon, Roche, Welwyn Garden City, UK)
every second day for 4 wk. The average rHuEpo dose was
2869 T 46 IU per injection and 11,308 T 986 IUIwkj1 for
KEN, whereas the average dose was 3741 T 383 per injec-
tion and 14,966 T 1530 IUIwkj1 for SCO group, reflecting
the higher body mass of the SCO cohort (74.8 T 7.9 kg vs
56.6 T 4.7 kg respectively). In one subject (KEN), the
predetermined safety hematocrit (HCT) limit of 55% was
reached on day 12 and saline injections substituted rHuEpo
on five occasions (14, 16, 18, 20, and 22 d after the first in-
jection). Thereafter, the subject resumed the standard rHuEpo
regimen. Daily oral iron supplementation (~100 mg of ele-
mental iron, ferrous sulfate tablets; Almus, Barnstaple, UK)
was given during the 4 wk of rHuEpo administration. Venous
blood samples were drawn from an antecubital vein into 4-mL
K2EDTA tubes (Greiner Bio-One Ltd., Stonehouse, UK) after
10 min of rest in the supine position (20). Before the analysis,
blood samples were rolled at room temperature for 2 min and
measured in triplicate using a Sysmex XT-2000i (Sysmex
UK, Milton Keynes, UK) for HCT, hemoglobin concentra-
tion (HGB) and reticulocyte percentage (RET%). The mean
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Three blood samples were taken at baseline over a period
of 2 wk, 10 blood samples during rHuEpo administration and
seven blood samples after rHuEpo administration over a 4-wk
period as previously described (4). The third baseline mea-
surement was used for paired comparisons to limit the potential
stress-induced hemoconcentration that may occur during the
first two visits (see KEN inF1 Fig. 1A and B). At baseline, resting
blood pressure and HR were assessed 3 times on both arms in
the supine position before blood sampling. Unlike in SCO,
total hemoglobin mass (tHbmass) was not measured in KEN
due to practical difficulties.
V˙O2max and running performance. V˙O2max was
determined at baseline, 2 to 3 d and 4 wk after the final
rHuEpo injection using a standard incremental test to ex-
haustion on a motorized treadmill (Cardionics Type 3113,
Bromma, Sweden). Briefly, after 15min of rest, running speed
was set at 9 kmIhj1 for 4 min with an incline of 1% and was
then increased by 1 kmIhj1Iminj1 to reach 17 kmIhj1.
Thereafter, the speed remained constant and the incline was
increased by 2.5%Iminj1 until volitional exhaustion. After
30 min of rest, V˙O2max was verified using a square-wave
protocol to exhaustion at a speed and incline equivalent to
the end of the incremental test. Gas exchange variables
were measured breath by breath using an automated meta-
bolic gas analysis system (K4b2; Cosmed, Rome, Italy).
For each stage, an average of the last 30 s was reported and
V˙O2max was declared as the highest average oxygen uptake
during a 30-s period. Additionally, attainment of V˙O2max
was confirmed if respiratory exchange ratio (R) (91.10) and
HR (T10 bpm of age-predicted maximum (i.e., 220 j
subject age)). Two 3000-m running time trials separated by
at least 1 d rest were performed on a 400 m outdoor athletics
track (Chepkoilel Stadium, Eldoret, Kenya) at an altitude of
~2150 m 2 to 3 d before, at the end of rHuEpo administration
and 4 wk after the final injection. Though the study was not
blinded, there was a concerted effort to be consistent and
minimize subjectivity, that is, limited verbal encouragement
with standardized feedback for split time and remaining laps
given in all the trials. The best performance of both trials on
each occasion was used for analysis. The typical error of
measurement for time trial performance calculated between
the two tests on each phase was 1.1%. Borg_s RPE was
recorded at the completion of the time trial. Temperature,
humidity and wind speed were recorded via portable
FIGURE 1—Mean T SD of changes in HCT (A), hemoglobin concentration (B), reticulocyte percent (C) and OFF score (D) in KEN (white squares) and
SCO (black circles). The gray zone represents the 4 wk of rHuEpo administration. Significant differences compared to the third baseline values in KEN
(n = 20) and SCO (n = 19) are indicated by solid and dashed lines P G 0.05, respectively.
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hygrometer and anemometer. During data collection, the
laboratory in East Africa was flooded resulting in the
damage of our metabolic gas analyzer and loss of some data
as reflected in the numbers presented inT1 Table 1.
Statistical analysis. Time trial performance, V˙O2max and
blood parameters data were analyzed using a two-way
ANOVA for repeated measures over time (two groups: SCO
vs KEN and three measurements: baseline, end of rHuEpo and
4 wk after the final injection). When F-statistic was significant
in the ANOVA, planned pairwise-specific comparisons were
carried out using Student_s paired, two-sample t test, Mann–
Whitney or Wilcoxon Signed Rank test where appropriate. A
one-way, repeated-measures ANOVA over time for each
group was also performed. Relationships between changes in
HGB, time trial performance and V˙O2max were assessed using
the Pearson_s product moment correlation coefficient. Statis-
tical significance was declared at P G 0.05. Data are described
as mean T SD. The results of KEN precede SCO when values
of the two groups are compared.
RESULTS
Hematological parameters. Hematocrit and HGB
were significantly higher in KEN compared with SCO at
baseline (HCT, 44.74% T 2.71% vs 41.54% T 2.0%; P G 0.001
and HGB, 14.9 T 0.9 gIdLj1 vs 14.2 T 0.8 gIdLj1; P = 0.017,
respectively, Fig. 1A and B). A main effect analysis showed
that, although HCT and HGB significantly increased in both
groups after rHuEpo administration (P G 0.01, Fig. 1A and B,
T2 Table 2), these blood parameters reached similar maximum
values approximately 3 wk after the rHuEpo administration
period (50.1% T 3.1% vs 49.2% T 1.9%, P = 0.96 and 16.8 T
1.2 gIdLj1 vs 16.6 T 0.8 gIdLj1, P = 0.551, respectively).
Between group differences in both HCT and HGB values
reappeared approximately 4 wk after the cessation of rHuEpo
administration (47.0% T 2.1% vs 45.1% T 1.7%, P G 0.05 and
16.1 T 0.8 gIdLj1 vs 15.6 T 0.7 gIdLj1, P G 0.05, respec-
tively) (Fig. 1A and B). RET% followed a similar pattern in
both groups (Fig. 1C). From similar baseline values, RET%
increased rapidly and significantly after the first week of
administration but attained lower values in KEN compared
to SCO during the rHuEpo administration (2.06% T 0.53%
vs 2.61% T 0.54%, P = 0.004) (Fig. 1C). Nadir was reached
approximately 2 wk after the last rHuEpo injection in KEN
and SCO (0.53% T 0.26% vs 0.41% T 0.13%, P = 0.169),
which were significantly lower compared to baseline
values in both groups (P G 0.001) (Fig. 1C). When both
groups were taken together, there was a significant interaction
(HCT: F2,114 = 6.98, P G 0.001; HGB: F2,114 = 3.97, P G
0.05). Regarding RET%, there were no interactions (F2,114 =
0.03, P = 0.96), and therefore, we analyzed the main effects
of rHuEpo (F2,114 = 142.32, P G 0.001) and altitude (F2,114 =
2.38, P = 0.13). OFF-score in KEN was significantly elevated
at baseline and until the third week of the rHuEpo administra-
tion compared with SCO (Fig. 1D). OFF-score significantly
decreased during the first 10 d of rHuEpo administration and
increased thereafter to reach maximum values 2 wk after the
last injection in both groups (Fig. 1D). One subject in KEN had
a distinctive hematological response to rHuEpo administration.
His baseline HCT (47.1%) and HGB (16.4 gIdLj1) remained
relatively stable throughout the study and the response in
RET% was blunted.
TABLE 1. Ventilatory parameters at maximal exertion in both cohorts at different phases of the study.
KEN SCO
Baseline End of rHuEpo End of the Study Baseline End of rHuEpo End of the Study
V˙O2max (mLIkg
j1Iminj1) 66.2a (4.9) 70.7ab (7.3) 68.2a (5.3) 57.7 (5.4) 62.1b (5.0) 60.3 (4.8)
V˙O2 (LImin
j1) 3.60a (0.32) 3.80a (0.48) 3.65a (0.41) 4.24 (0.41) 4.54b (0.46) 4.43 (0.49)
V˙CO2 (LImin
j1) 3.74a (0.31) 4.14ab (0.55) 4.25a,b (0.37) 4.57 (0.42) 4.95b (0.64) 4.68 (0.46)
V˙E/V˙O2 42.1
a (3.6) 40.5a (6.3) 43.0a (4.8) 34.8 (3.3) 33.2 (4.4) 32.8 (3.3)
V˙E/V˙CO2 40.2
a (3.2) 34.8ab (2.7) 37.2a,b (3.8) 32.3 (3.4) 30.2b (2.6) 30.9 (2.9)
RR (bpm) 65 (5) 62 (5) 63 (9) 61 (8) 59 (7) 58 (9)
PETO2 (mm Hg) 84
a (2) 83a (4) 85a (2) 115 (3) 113 (5) 113 (4)
PETCO2 (mm Hg) 31
a (3) 34ab (2) 33a (3) 36 (4) 39b (4) 38 (3)
R 1.04 (0.03) 1.10 (0.12) 1.18b (0.12) 1.07 (0.04) 1.08 (0.08) 1.06 (0.07)
V˙E (LImin
j1) 145.0 (21.1) 146.8 (18.5) 154.8 (13.3) 150.3 (15.6) 150.8 (17.5) 148.5 (13.7)
HR (bpm) 185 (7) 188 (6) 189a (6) 184 (9) 183 (6) 181 (10)
Values are mean T SD. Significant differences in KEN compared with SCO are indicated by aP G 0.05. Significant differences compared to baseline values in both groups are indicated by
bP G 0.05. KEN, n = 12 unless indicated otherwise; SCO, n = 14 unless indicated otherwise; V˙O2max (mLIkg
j1Iminj1), V˙O2 (L
.minj1, KEN = 9), and V˙CO2 (KEN = 9); V˙E/V˙O2, ventilatory
equivalent for oxygen (KEN = 11), V˙E/V˙CO2, ventilatory equivalent for carbon dioxide; RR, respiratory rate; PETO2, end tidal partial pressure for O2; R, respiratory quotient (KEN = 9); V˙E,
respiratory minute ventilation (KEN = 11) and HR (SCO = 5).
TABLE 2. Relative changes in running performance and blood parameters in KEN and SCO.
KEN SCO
End of rHuEpo End of the Study End of rHuEpo End of the Study
Hematocrit 9.7 T 4.7%a,b 4.1 T 5.0%a,b 17.6 T 4.9%b 7.8 T 4.5%b
Hemoglobin concentration 10.1 T 5.5%a,b 5.9 T 5.8%b 16.2 T 5.2%b 8.2 T 5.1%b
3000 m performance j4.6 T 2.4%b j3.3 T 2.6%b j5.7 T 2.5%b j3.4 T 2.6%b
Maximal oxygen uptake 5.8 T 8.0%b 2.6 T 8.6% 8.1 T 6.8%b 4.4 T 5.6%b
Values are mean T SD (95% confidence intervals). Significant differences in KEN compared to SCO are indicated by aP G 0.05. Significant differences compared to baseline values in both
groups are indicated by bP G 0.05. 15 KEN and 19 SCO subjects were included in the analysis of time trial performance, 12 KEN and 14 SCO subjects were included in the analysis of
V˙O2max and 20 KEN and 19 SCO subjects were included for analysis of the other variables.
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V˙O2max and running performance. Both time trial
performance and relative V˙O2max were significantly better in
KEN compared with SCO at baseline (9:24 T 0:28 min:s vs
11:08 T 1:15 min:s, P G 0.001 and 66.2 T 4.9 mLIkgj1Iminj1
vs 57.7 T 5.4 mLIkgj1Iminj1, P G 0.001) after rHuEpo ad-
ministration (8:57 T 0:23 min:s vs 10:30 T 1:07 min:s, P G 0.001
and 70.7 T 7.3 mLIkgj1Iminj1 vs 62.1 T 5.0 mLIkgj1Iminj1,
P G 0.001) and 4 wk postadministration (9:05 T 0:21 min:s vs
10:46 T 1:13 min:s, P G 0.001 and 68.2 T 5.3 mLIkgj1Iminj1
vs 60.3 T 4.8 mLIkgj1Iminj1, P G 0.001,F2 Fig. 2,T3 Table 3).
However, the relative improvements were not significantly
different between the two groups for time trial performance as
well as for V˙O2max immediately postadministration and 4 wk
after rHuEpo (Table 2). Across group analysis revealed that
there were no interaction effects of V˙O2max (F2,114 = 0.038,
P = 0.89) and time trial (F2,114 = 0.16, P = 0.87, Table 2).
The subject who had a blunted hematological response did
not improve upon his baseline time trial performance im-
mediately after rHuEpo administration or 4 wk after the final
rHuEpo injection (~9:29 min:s at each phase). Unlike SCO
whose RPE posttime trial remained relatively constant
throughout the study, RPE in KEN increased at the end of
rHuEpo compared to baseline (Table 3). Time trial perfor-
mance was significantly correlated with V˙O2max throughout
the study when KEN was grouped with SCO (r 9j0.78, P G
0.001) but not when KEN alone was analyzed (r =
Gj0.26, P 9 0.337). A significant correlation in indi-
vidual responses compared to baseline was observed for
time trial performance and V˙O2max at the end of rHuEpo
when KEN was analyzed alone and when grouped with SCO
(r = j0.86, P G 0.001, r = j0.62, P G 0.001, respectively).
The relative improvement was higher in the third lap as
compared to the second (Table 3). However, there was no
significant correlation between HGB and either time trial
performance or V˙O2max.
At maximal exertion, V˙O2 relative to body mass was
higher in KEN than in SCO; however, owing to their lower
body mass, KEN had a lower absolute V˙O2 at maximal ex-
ertion at all time points (Table 1). At maximal exercise, V˙O2
in relative (mLIkgj1Iminj1) terms, carbon dioxide produc-
tion (V˙CO2), ventilatory equivalent for CO2 (V˙E/V˙CO2) and
end tidal partial pressure for CO2 (PETCO2) were signifi-
cantly higher at the end of rHuEpo administration in both
groups. While in absolute terms, V˙O2 (LImin
j1) increased in
both KEN and SCO, it was only significant in SCO (3.60 T
0.32 LIminj1 vs 3.80 T 0.48 LIminj1, P = 0.147 and 4.24 T
0.41 LIminj1 vs 4.54 T 0.46 LIminj1, P G 0.05 respectively)
(Table 1). At the end of the study, V˙CO2 was significantly
higher and V˙E/V˙CO2 was significantly lower at maximal
exercise in KEN compared to baseline, whereas there were
no significant changes compared with baseline in SCO
(Table 1). There was a trend for PETCO2 to be higher in
TABLE 3. Running 3000 m time trial performance and V˙O2max in KEN.
KEN
Baseline End of rHuEpo End of the Study
3000 m time trial 3000 m total time (min:s) 9:24 T 0:28 8:57 T 0:23a 9:05 T 0:21a
First 1 km split time (min:s) 3:03 T 0:08 2:57 T 0:08a 2:58 T 0:08a
Second 1 km split time (min:s) 3:12 T 0:11 3:03 T 0:09a 3:04 T 0:08a
Third 1 km split time (min:s) 3:09 T 0:11 2:59 T 0:09a 3:03 T 0:09a
RPE scale (6–20) 14.6 T 1.5 16.1 T 1.1a 15.3 T 1.2
Temperature (-C) 24.0 T 2.5 25.4 T 2.4 23.3 T 3.9
Humidity (%) 55.4 T 16.1 50.4 T 9.2 58.5 T 15.9
Wind speed (mIsj1) 1.6 T 0.8 1.9 T 0.8 2.8 T 0.7a
Max test V˙O2max (LImin
j1) 3.60 T 0.32 3.80 T 0.80 3.65 T 0.41
V˙O2max (mLIkg
j1Iminj1) 66.2 T 4.9 70.7 T 7.3a 68.2 T 5.3
Values are mean T SD. Significant differences compared to baseline values are indicated by aP G 0.05. A total of 15, 9, and 12 KEN subjects were included in the analysis of the time trial,
V˙O2max in absolute (LImin
j1) and in relative (mLIkgj1Iminj1) terms, respectively: Kenyan runners living and training at moderate altitude. RPE: Borg’s RPE.
FIGURE 2—Mean T SD changes in 3,000 m running time trial performance (A), and V˙O2max (B) at baseline, immediately after the rHuEpo ad-
ministration (i.e., end of rHuEpo) and 4 wk after the administration (i.e., end of the study) in KEN (white squares) and SCO (black circles). 15 KEN and
19 SCO subjects were included in the analysis of time trial performance and 12 KEN and 14 SCO subjects were included in the analysis of V˙O2max
Significant differences in KEN compared with SCO are indicated by *P G 0.05. Significant differences compared to baseline values in both groups are
indicated by †P G 0.05.
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KEN at the end of the study; however, this failed to reach
statistical significance (P = 0.054). KEN had a lower resting
systolic blood pressure (122 T 6 vs 128 T 9, P = 0.005) and
HR (57 T 8 vs 62 T 8, P = 0.024) compared with SCO but
similar diastolic blood pressure (67 T 5 vs 70 T 8, P = 0.12).
No significant changes were observed after rHuEpo ad-
ministration in resting systolic and diastolic blood pressure
or resting HR; however, at maximal exercise, HR was sig-
nificantly higher in KEN compared with SCO at the end of
the study period (189 T 6 bpm vs 181 T 10 bpm, respec-
tively; P G 0.05).
DISCUSSION
This study is the first to report the effects of rHuEpo ad-
ministration on blood parameters, V˙O2max and running time
trial performance in Kenyan endurance runners living and
training at moderate altitude (~2150 m) compared with data
reported in white trained males living and training at or near
sea level (4). Although baseline values were markedly dif-
ferent between the groups and blood parameters did not
change as much in KEN as in SCO, the relative improve-
ments in running performance immediately after rHuEpo
administration (~5%) and 4 wk after the final injection
(~3%) were relatively similar in both groups. Although ox-
ygen carrying capacity of the blood was not directly mea-
sured in the present study, it is tempting to conclude that not
all the potential ergogenic benefit provided by the increase
in HGB was used given the improvement in performance
was less than the increase in HGB; the reason(s) for this
remains to be determined.
The mean HGB and HCT level reported in our study were
a little lower but generally in accordance with the values
previously reported in the literature (21,22). This small dif-
ference may be due to the posture adopted before blood
sampling, which was not reported in the other studies and
may affect hematological parameters (20). Regardless of
these minor discrepancies, baseline HCT and HGB values
were, as expected, higher in KEN than SCO (Table 2 and
Fig. 1). There was also a significant increase in RET% after
rHuEpo administration (Fig. 1C). HCT and HGB continued
to rise significantly in both groups reaching a maximum of
approximately 50% and 17 gIdLj1 1 wk after the cessation
of rHuEpo administration respectively. Although increasing
HGB enhances the blood oxygen carrying capacity, it is also
associated with elevated blood viscosity, which in turn can
limit capillary flow, increase cardiac work and impair exer-
cise performance (22,23). However, the moderate altitude
(2000–2500 m) at which Kenyan endurance athletes typically
live and train may represent an optimal altitude to increase
endogenous erythropoietin production and consequently,
augmented HCT and performance. Although not universally
accepted, some authors reported that the optimal HCT for
human exercise performance should be within the broad
range of 43% to 55% (23,24). Others have speculated that it
should be close to the measurements reported in a Finnish
cross-country skier and three times Olympic gold medalist
with an autosomal dominant mutation in erythropoietin receptor
resulting in a higher than normal HCT and HGB above 65%
and 20 gIdLj1, respectively (22,25). Interestingly, a study
comprising of 217 male and 200 female elite speed skaters
failed to find an association between HGB and skating per-
formance (26). The suggestion of an elevated blood viscosity
after rHuEpo administration in the present study, illustrated
by the increase in HCT and HGB which peaked at similar
times and levels in both groups, did not appear to hinder
significant improvements in running performance either in
KEN or in SCO. This finding is in agreement with a study by
Calbet et al (27) where after 9 wk at 5260 m above sea level,
HGB increased by 36% but this increased blood viscosity did
not impair maximal cardiac output during maximal exercise
at altitude nor did subsequently decreasing the HGB by 24%
via hemodilution. Consequently, the effect of the small in-
crease in blood viscosity assumed by the modest increase in
HCT in the present study is too small to have any real impact
on peak cardiac output.
In the present study, an average improvement of 27 s
(corresponding to a ~5% improvement) during the 3000 m
run at ~2150 m above sea level after rHuEpo administration
was found. While the hematological changes after rHuEpo
were not as pronounced in KEN as in SCO, reflected by an
increase in HGB and HCT of ~10% in KEN compared with
~17% in SCO, the relative improvements in running perfor-
mance and V˙O2max were comparable (~5 vs ~7%). Similar
percent changes in all the phases between groups justified the
changes in performance variables were mostly related to
rHuEpo. Despite some methodological differences in the
frequency of injections and in the dosage used, rHuEpo ad-
ministration for 4 to 6 wk has been shown to increase V˙O2max
by approximately 6% to 8% in normoxia (1–8).
Despite the overwhelming scientific evidence to support
the ergogenic effects of rHuEpo, some question the appli-
cation of these primarily laboratory findings to real-life
competitive conditions or races involving elite athletes
(10,11). For example, Heuberger et al (10) reported that
while performance was enhanced in laboratory-based high-
intensity tests, endurance and road race performances were
similar between rHuEpo and placebo groups questioning a
multitude of findings which state otherwise (1–8). The dif-
ference in subject characteristics, mode, and intensity of the
performance tests may account for some of the lack of
agreement between their findings and the current study. Fur-
thermore, the current study was not double-blind, and there-
fore, the extent of the placebo-effect cannot be quantified.
It has previously been reported that the relative improve-
ment of V˙O2max induced by rHuEpo administration was
more than doubled (i.e., 17.5 vs ~8%) at a simulated mod-
erate altitude up to 3500 m compared with normoxia (16).
Despite the smaller increase in the hematological parameters
in KEN after rHuEpo administration, improvements in
V˙O2max and time trial performance was similar between
KEN compared with SCO (Table 2). Absolute V˙O2max in
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KEN increased but not significantly (P = 0.147) after the end
of rHuEpo administration, this however may be due to a lack
of statistical power after the loss of some data after a severe
flood in the laboratory. The Kenyan athletes recruited in the
present study were chronically adapted to moderate-altitude
and were of a higher training status than their counterparts in
SCO. It is therefore likely that KEN athletes had a larger
cardiac output and may have subsequently desaturated to a
greater extent when exercising at V˙O2max after rHuEpo ad-
ministration. The mode of testing could be another factor
because desaturation is more common during running than
during bicycling (28). The present data revealed a decrease
in V˙E/V˙CO2 despite an increase in PETCO2, potentially
reflecting a ventilatory limitation in these athletes. As de-
scribed by Foster et al (29), a ventilatory limitation is most
likely primarily due to mechanical stress in the lung. Using
data presented by Foster et al (29), equation by Severinghaus
(30) and the PETO2 data in KEN in the present study, arterial
oxygen saturation (SaO2) during maximal exercise can be
estimated. Before rHuEpo administration and at an altitude of
approximately 2150 m, the KEN athletes had an estimated
SaO2 of 91% at V˙O2max. This level of SaO2 is similar to that
reported at maximal exercise when endurance-trained athletes
were exposed acutely to an altitude of 2500 m (i.e., albeit
normobaric hypoxia): 91.3% T 1.9% at V˙O2max (31). This
similar SaO2 at maximal exercise in the chronically adapted
to altitude KEN athletes in the present study and sea-level
endurance athletes exposed to a similar degree of hypoxia
(31) suggests similar limitations in pulmonary gas exchange
during maximal exercise. Specifically, the large cardiac out-
put of endurance-trained athletes at maximal exercise and
consequently, the reduced transit time of red blood cells
across the alveoli, would be expected to decrease SaO2. This
limitation in pulmonary gas exchange during maximal exer-
cise could explain the lack of significant difference in abso-
lute V˙O2max when O2 carrying capacity was increased after
rHuEpo in the present study (Table 1).
The ergogenic effects of rHuEpo administration appear to
be explained primarily by an increase in oxygen carrying
capacity as no measurable nonhematopoietic ergogenic ef-
fect of rHuEpo on exercise performance in normoxic con-
ditions was observed in two separate studies conducted by
the same research group (32,33). The oxygen supply to
exercising muscle depends on the HGB and cardiac output.
However, HGB is only weakly related to V˙O2max, whereas
the relationship between tHbmass and V˙O2max is much
stronger (34). Unlike HGB, tHbmass is not affected by
changes in plasma volume and is therefore a key comple-
mentary parameter to evaluate blood oxygen carrying ca-
pacity (34). Living and training at moderate altitude has
been shown to increase blood volume and tHbmass in en-
durance athletes (35), and therefore, it would have been
useful to have also measured tHbmass in addition to the other
blood-related parameters to better account for the observed
changes in V˙O2max. A direct comparison of the effect of
rHuEpo in the two cohorts cannot be performed without
information on, at least, SaO2 as elite athletes desaturate
more at altitude than nonelite athletes and this effect is
proportional to that of V˙O2max (36). The present study was
designed primarily to identify differentially expressed gene
transcripts and therefore, SaO2 and tHbmass were not mea-
sured for practical reasons nor was the study blinded or in-
clude a control group. Therefore, the novel data generated
within the study limitations, although useful for comparison
with the literature, require further replication. The altitude
and sea-level comparison is secondary and given the limi-
tations outlined should be interpreted with caution. Factors
unrelated to rHuEpo such as altered motivation (e.g., pla-
cebo, order effect) may partly explain the reported perfor-
mance effects and reflected in the small but significant rise
in RPE after rHuEpo in KEN. Proponents of ‘‘PlacEpo’’
claimed that the true contribution of doping is overestimated
as the claimed 3%–6% improvement in V˙O2max by rHuEpo
doping is similar to the day-to-day variation (37). Studies
have shown that placebo can improve 3000 m race time by
1.2% (38) and V˙O2max by 0% to 1.5% (1,9) and therefore,
much less than observed in the present study (~5% vs 5%–7%,
respectively). Nevertheless, it is tempting to speculate that the
similar relative improvements in running performance and
V˙O2max, despite the blunted hematological response in KEN
may be due to mechanisms unrelated to blood oxygen car-
rying capacity, such as a greater recruitment of motor units
(39) and mood alterations (18) that can influence training and
performance due to the substantial socioeconomic rewards
that are perceived to come with performance success (13).
In the present study, the subjects achieved a higher per-
ception of effort at the end of the rHuEpo trial (Table 3).
Several studies (18,32,40) describe the presence of erythro-
poietin receptors in heart, brain, and striated muscle tissues,
and therefore, a potential central mechanism of action of
rHuEpo in addition to the well-established enhanced oxygen
carrying capacity. Recently, the understanding of the way in
which rHuEpo exerts its effects have advanced with our re-
cent gene expression studies (41), identifying differentially
expressed gene transcripts relevant to the transport of oxygen,
carbon dioxide and blood pH regulation (e.g., hemoglobin
delta, 2,3-bisphosphoglycerate mutase, carbonic anhydrase I
and solute carrier family 4, anion exchanger-member 1).
Based on the blunted response in the hematological pa-
rameters and exercise performance, one Kenyan subject was
classified as a ‘‘nonresponder’’ to rHuEpo administration. It
is well known that there is marked variability in the sensi-
tivity to rHuEpo in anaemic patients as well as in rHuEpo
dose requirement (42). In addition, the sensitivity to hypoxia
exposure during altitude training in healthy volunteers or
athletes is also variable as reflected by significant but not
clear-cut differences in plasma erythropoietin concentrations
(43,44). Athletes who responded to altitude training dem-
onstrated higher erythropoietin levels which in turn seemed
to trigger a sufficient increase in tHbmass and associated
improvements in exercise performance (43,44). The particular
subject in KEN who demonstrated a blunted hematological
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and exercise performance response after rHuEpo may there-
fore be representative of the 10% of the treated patients or of
the ‘‘nonresponders’’ to altitude training. In stark contrast,
another subject in the present study was required to prema-
turely discontinue rHuEpo injections due to his pronounced
response in HCT. This subject achieved the predetermined
health limit of 55% after 2 wk of rHuEpo use and reported
moderate-severe headaches after training.
The use of rHuEpo is prohibited by the World Anti-
Doping Agency. The direct urinary test to detect rHuEpo
was developed and published by Lasne et al in 2000 (45).
However, although the effects of rHuEpo administration on
hematological parameters and exercise performance can last
for several weeks, as shown in the present study, the test has
a rather limited detection window, that is, a few hours up to
a few days depending on the dose used. This limitation in
detection has prompted the development of indirect tests to
detect rHuEpo using blood markers of altered erythropoiesis
(3). The ABP method was introduced as a new tool to in-
directly detect blood doping as well as to intelligently target
athletes for additional testing (19). The ABP approach relies
on identifying intra-individual abnormal variability over
time of selected hematological parameters including HGB,
HCT, RET% and OFF-score (46). In this context, factors
such as residence at altitude and ethnicity have been shown
to significantly influence these hematological parameters
(47) and confirmed in the present study as the magnitude of
change in HGB, RET%, and OFF-score used in the ABP
was reduced in KEN as compared with SCO in response to
the same rHuEpo administration regimen. As a result, it may
be more difficult to detect rHuEpo doping at altitude com-
pared to sea level using the current antidoping methods due
to the blunted hematological response. There are indeed
concerns about the risk of the misuse of altitude exposure by
some athletes to mask blood doping practices, such as the
administration of rHuEpo.
In conclusion, this is the first study to demonstrate that
4 wk of rHuEpo administration significantly increased
the already relatively high basal HGB and HCT values of
Kenyan endurance runners living and training at moderate
altitude by ~10%. Although the rHuEpo-induced increase
in key hematological parameters in these altitude-adapted
Kenyan endurance runners was blunted compared with white
athletes living and training at or near sea level, the relative
improvements of ~5% and ~3% in running performance im-
mediately after the rHuEpo administration and 4 wk after the
last injection, respectively, were similar in both groups. This
finding is also in line with the overwhelming scientific litera-
ture. Although caution is required when extrapolating findings
from subelite to truly elite athletes, the significant improve-
ments in running performance we report would almost certainly
translate into a worthwhile enhancement in elite performance.
Moreover, in professional cycling stage races, such as the Tour
de France, the mountain stages, which peak at altitudes ranging
from approximately 1500 m to above 2500 m, often separates
winners from contenders. If the ergogenic effects of rHuEpo are
indeed enhanced at moderate altitude or can at least signifi-
cantly reduce the hypoxia-induced impairment in exercise per-
formance, rHuEpo administration has the potential to improve
further the athlete_s chance of winning the key stages and the
overall classification. However, further research with larger
sample size, complete data set, measurement of tHbmass,
arterial blood gases, SaO2 and improved experimental de-
sign (e.g., randomized, placebo-controlled crossover study
design) is required to confirm these findings. The results
from this study also have important implications for current
antidoping practices.
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